Tonix Pharmaceuticals Holding Corp. (TNXP)
3.01
-0.23
(-7.10%)
USD |
NASDAQ |
Nov 13, 16:00
3.06
+0.05
(+1.66%)
After-Hours: 19:59
Tonix Pharmaceuticals Enterprise Value : -99.49M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | -99.49M |
| November 11, 2026 | -87.43M |
| November 10, 2026 | -83.02M |
| November 09, 2026 | -75.56M |
| November 06, 2026 | -70.77M |
| November 05, 2026 | -73.45M |
| November 04, 2026 | -63.68M |
| November 03, 2026 | -62.15M |
| November 02, 2026 | -62.92M |
| October 30, 2026 | -63.87M |
| October 29, 2026 | -60.43M |
| October 28, 2026 | -58.70M |
| October 27, 2026 | -58.32M |
| October 26, 2026 | -60.04M |
| October 23, 2026 | -62.53M |
| October 22, 2026 | -63.30M |
| October 21, 2026 | -57.55M |
| October 20, 2026 | -50.85M |
| October 19, 2026 | -51.81M |
| October 16, 2026 | -45.87M |
| October 15, 2026 | -38.60M |
| October 14, 2026 | -38.98M |
| October 13, 2026 | -44.15M |
| October 12, 2026 | -34.38M |
| October 09, 2026 | -21.74M |
| Date | Value |
|---|---|
| October 08, 2026 | -22.13M |
| October 07, 2026 | -16.96M |
| October 06, 2026 | -14.18M |
| October 05, 2026 | -6.998M |
| October 02, 2026 | 9.088M |
| October 01, 2026 | 15.22M |
| September 30, 2026 | 24.98M |
| September 29, 2026 | -12.91M |
| September 28, 2026 | -8.716M |
| September 25, 2026 | -9.388M |
| September 24, 2026 | -12.07M |
| September 23, 2026 | -3.007M |
| September 22, 2026 | 2.870M |
| September 21, 2026 | 5.054M |
| September 18, 2026 | 7.572M |
| September 17, 2026 | 16.81M |
| September 16, 2026 | 22.52M |
| September 15, 2026 | 20.17M |
| September 14, 2026 | 22.01M |
| September 11, 2026 | 24.36M |
| September 10, 2026 | 31.25M |
| September 09, 2026 | 40.49M |
| September 08, 2026 | 46.03M |
| September 04, 2026 | 45.69M |
| September 03, 2026 | 49.55M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Heron Therapeutics, Inc. | 171.22M |
| Inovio Pharmaceuticals, Inc. | 119.79M |
| Nektar Therapeutics | 722.92M |
| Karyopharm Therapeutics, Inc. | 191.67M |
| Minerva Neurosciences, Inc. | 113.30M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -53.33M |
| Revenue (Quarterly) | 17.23M |
| Total Expenses (Quarterly) | 70.56M |
| EPS Diluted (Quarterly) | -2.892 |
| Gross Profit Margin (Quarterly) | 89.00% |
| Profit Margin (Quarterly) | -309.4% |
| Earnings Yield | -406.6% |
| Normalized Earnings Yield | -406.57 |